European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Etherna Immunotherapies N.V., Niel, Belgium

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Etherna Immunotherapies N.V.
Etherna N.V.

Identification

Kbo
Crossroads Bank for Enterprises (KBO) 0502.703.389
Sirul
Siren 911407393
Siret
Siret 91140739300014
Lei
875500KLYW21WUXR5V59
EUID
BEKBOBCE.0502.703.389

Address

Galileilaan 19, 2845 Niel, Belgium
Kortenberg, Belgium

Corporate purpose

72.11
Research and experimental development on biotechnology

Biotechnology Research and Development

Financials

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Publications

14 Jul 2025 in Hor
EU funding: Next Generation Immune Checkpoint Inhibitor for Cancer Therapy
16 Jun 2025 via Fund+ N.V. also 28/06/2024, 08/06/2022
Shareholder: Fund+ N.V
10 Jun 2025 via Flandersbio VZW also 18/07/2024
No longer Member of the board: Flandersbio VZW
27 May 2025
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024 · Auditor: Antonin Rollet · Board (3) …
23 May 2025 via Participatiemaatschappij Vlaanderen N.V. also 27/05/2024, 17/05/2023, 23/05/2022
Shareholder: Participatiemaatschappij Vlaanderen N.V
16 May 2025 via Progress Pharma N.V. also 27/06/2024, 20/06/2023, 04/07/2022
Shareholder: Progress Pharma N.V
18 Mar 2025
ARTICLES OF ASSOCIATION (TRANSLATION, COORDINATION, OTHER AMENDMENTS), CAPITAL, SHARES
5 Nov 2024
Member of the board (4) · CEO (1) · Auditor (1)
21 Jun 2024
Authorized signatory (3)
15 May 2024
Director-General: Bernard Sagaert · No longer CEO: Russell Greig · CEO (1)
7 May 2024
Annual report for the year ending 31/12/2023 · Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023 · Auditor: Marinus E. Dekkers · Board (3) …
20 Mar 2024
Wordmark: “ETHERNA“
15 Feb 2024 in Sat
State Aid (€1,697,986): Decision O&O Knowledge Intensive
Year 2023 in Epobase
5 European patent filings: Ionizable Lipids …
6 Jun 2023
Manager: Philip Chase · Member of the board (4)
25 May 2023 via Flandersbio VZW also 12/07/2022
Member of the board: Flandersbio VZW
9 May 2023
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022 · Board (3) · Shareholding: Nanjing Aurorna Biotechnology Company Ltd.  …
20 Mar 2023
Member of the board (6)
Year 2022 in Epobase
5 European patent filings: Immunostimulatory Mrna Compositions and Uses Thereof …
22 Sept 2022
No longer Director-General: Steven Powell · Authorized signatory (1)
22 Aug 2022
Director (4) · Manager (4) · Capital: €1,978,555 · Company statute
20 Jul 2022
Director: Chris Buyse, John De Koning, Vincent Ossipow · No longer Director (3)
23 May 2022
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021 · No longer Board (7) …
26 Jan 2022
Persons
Year 2021 in Epobase
5 European patent filings: Ionizable Lipids …
22 Dec 2021 via C.H. Boehringer Sohn AG & Co. KG
Shareholder: C.H. Boehringer Sohn AG & Co. KG
2 Dec 2021 in France
Address · Legal form · Name: ETHERNA IMMUNOTHERAPIES SA · Segment clas­si­fi­ca­tion
24 Nov 2021
Frank A. Kalkbrenner
4 Feb 2021
Director (1) · Capital: €1,285,220 · Company statute
1 Feb 2021 in Hor
EU funding (€5,094,401): Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine
11 Aug 2020
No longer Auditor (2) · Capital: €1,039,450
Year 2020 in Epobase
4 European patent filings: Combination Mrna Therapy for USE in the Treatment of Metastatic Melanoma …
28 Jun 2020
No longer Director: Chris De Jonghe · Director (4) · Auditor (1) · Capital: €992,186 · Company statute
25 Jun 2020
No longer Director: Chris De Jonghe · Director (2)
29 Apr 2020
Authorized signatory: Steven Powell
13 Feb 2020 via Boehringer Ingelheim Corporate Center GmbH
Shareholder: Boehringer Ingelheim Corporate Center GmbH
13 Feb 2020 in Sat
State Aid (€824,064): Decision O&O Knowledge Intensive
23 Jul 2019
No longer Director: Kostka Marcus · Director (1) · Auditor (1) · Capital: €787,510
9 Jul 2019 in Hor
EU funding (€5,431,013): EXpanding Platforms for Efficacious mRNA Therapeutics
14 Feb 2019
Director: Chris De Jonghe, Alexandra Tolia · No longer Director: Philippe Monteyne
11 Feb 2019
Capital: €515,711
18 Jan 2019
Patent: Lipid Nanoparticles
23 Oct 2018
Manager: Steven Powell
24 Apr 2018
Capital: €515,443 · Company statute
29 Jan 2018
No longer Director: Dirk Reyn
20 Dec 2017
Capital: €10.7M
14 Sept 2017 in Sat
State Aid (€1,056,697): R&D&I-scheme Flanders. Prolongation of an existing R&D&I-scheme. Belgium (Flanders)
9 May 2017
Capital: €383,042 · Company statute
19 Dec 2016 in Hor
EU funding (€215,000): Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection
28 Nov 2016
Managing Director: Dirk Reyn · Auditor (1)
23 Sept 2016
Director (9) · Authorized signatory (4)
27 Jun 2016 as Etherna N.V.
Annual report for the year ending 31/12/2015 (only deposited)
8 Apr 2016 as Etherna N.V.
Member of the board (9) · Manager (5) · Address · Capital: €212,813 · Name · Company statute
10 Jun 2015 as Etherna N.V.
Managing Director: Dirk Reyn · Director (1) · No longer Director (1)
29 May 2015 as Etherna N.V.
Annual report for the year ending 31/12/2014 (only deposited)
28 Jul 2014 as Etherna BVBA
Director (4) · Shareholder (3) · Auditor (1) · Capital: €61,500 · Legal form · Company statute
13 Jun 2014 as Etherna BVBA
Annual report for the year ending 31/12/2013 (only deposited)
14 May 2014 as Etherna BVBA
Manager (2) · Capital: €50,426 · Company statute
29 Jan 2014 as Etherna BVBA
Director (1)
1 Dec 2013 in Fts
EU funding (€1,481,569): Grant FP7 - 602570 - Ihivarna
23 Jan 2013 as Etherna BVBA
Reg­is­tra­tion: 23/01/2013 · Director (3) · Capital: €18,600.00
17 Jan 2013
Managing Director: Dirk Reyn
There are no publications matching your search.

Mentions

1 Aug 2025 in Kbo also 28/07/2025
Member of the board: Administratiekantoor eTheRNA Immunotherapies PS
5 Dec 2024 in Rne
Reg­is­tra­tion: 02/12/2021 · Segment clas­si­fi­ca­tion · Biotechnology Research and Development
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Etherna Immunotherapies N.V., Niel, Belgium" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.